tbuckley/cabot-search huggingface dataset:
Abstract 11873: Feasibility of, and Adherence to, a Novel, Home-based Cardiac Tele-rehabilitation Program for Heart Attack Survivors: The MI-PACE Study
Authors: Emily Ensom, Daniella Albuquerque, Nathaniel Erskine, Amy Peterson, Emily Dickson, Eric Y Ding, Jaclyn Piche, Ziyue Wang, Jorge Escobar, Alvaro A Alonso, Raghavendra Makam, Naomi Botkin, Wim Stut, David D McManus
Journal: Circulation (2019)

Introduction: Through supervised exercise training and disease management interventions, cardiac rehabilitation (CR) reduces morbidity and mortality among acute myocardial infarction (AMI) survivor...
Abstract 11618: Predicting the Cost-Effectiveness of Cardiovascular Interventions Across Multiple Settings: A Model-based Approach to Guide Global Health Policy
Authors: Saate S Shakil, Katherine L Rosettie, Gregory A Roth, Lauryn Stafford, Marcia R Weaver
Journal: Circulation (2019)

Background: Cost-effectiveness analyses (CEA) are a useful tool for policymakers in prioritizing health interventions, but can be challenging to interpret beyond the country in which they are perfo...
Abstract 15937: Early Circulating Procollagen Type I Carboxy-Terminal Propeptide Levels After Acute Myocardial Infarction Correlate With Scar Size
Authors: Helen E Driessen, Bas R van Klarenbosch, Bart J Kok, Marc A Vos, Maarten J Cramer, Steven A Chamuleau, Toon A van Veen, Birgitta K Velthuis, Sanne de Jong
Journal: Circulation (2018)

Introduction: Because of increased survival after myocardial infarction (MI), heart failure due to adverse remodeling is a growing socio-economic burden. A major hallmark of adverse remodeling is i...
Clinical and molecular characteristics of early-onset versus average-onset esophagogastric cancer.
Authors: Melissa Amy Lumish, Shalom Sabwa, Steven Brad Maron, Geoffrey Yuyat Ku, David H. Ilson, Elizabeth Won, Jia Li, Smita Suhas Joshi, Ping Gu, Vivian E. Strong, Daniela Molena, David Randolph Jones, Smita Sihag, Daniel G. Coit, Sam S. Yoon, Laura H. Tang, Jaclyn Frances Hechtman, Yelena Y. Janjigian, Andrea Cercek
Journal: Journal of Clinical Oncology (2021)

250 Background: While the rate of esophagogastric (EG) cancer is declining, early onset (EO) gastric cancer prior to age 50 is rising. It is unknown whether EO-EG cancer represents a distinct entity. This study investigates the clinical and molecular characteristics of EO compared with average onset (AO)-EG cancers. Methods: We reviewed clinical and molecular features of gastric (G), esophageal (E) and gastroesophageal junction (GEJ) cancer in patients treated at MSKCC between 2005 and 2018. We defined early onset as age &lt; 49, based on the age cutoff for urgent endoscopy referral. Clinical symptoms at diagnosis, primary tumor location, histology, HER2 and MSI status and molecular alterations were compared using Fisher’s exact test. Benjamini-Hochberg method was used to decrease the false discovery rate. Results: We analyzed 738 pts with EG cancer (age &lt; 49 n=151; age &gt;50 n=587). Race and sex were different with more Asian (19% vs. 9%), fewer Caucasian (62% vs. 81%) ( P&lt;0.001) and more female patients (40% vs. 29%, P=0.014) in the EO group. Time from symptom onset to diagnosis was longer in the EO group (median (IQR) 144 d (66-276) vs. 75 d (34-136), P=0.009), though stage did not differ ( P=0.49). Patients with EO-EG cancer had less weight loss ( P&lt;0.001), but no other distinct presenting symptoms. Primary disease site was different with more gastric in the EO group (66% vs. 55%, P=0.04). Signet-ring histology was more common in the EO group (11% vs. 3%; P=0.0009). ERBB2 amp and MSI-H were similar, with a trend toward more MSI-H in the AO group (ERBB2 amp P=0.88, Q=0.830; MSI-H P=0.0157, Q=0.056). The most frequent somatic alterations were similar in EO vs. AO pts, including TP53 (68% vs. 70%, P=0.370, Q=0.825), CDH1 (15% vs. 11%, P=0.139, Q=0.825), RHOA (6% vs. 5%, P=0.395, Q=0.825). There was a trend toward more ARID1A (19% vs. 7%, P&lt;0.01, Q=0.250) and FBWX7 (5% vs. 2%, P=139, Q=0.825) mutations in the AO group. Conclusions: Presenting symptoms, stage, histology, HER2 and MSI status are similar in patients with EO vs. AO-EG cancer. There is a trend in EO toward longer time to diagnosis, gastric primary site of disease, signet-ring histology and fewer ARID1A and FBWX7 mutations. Expanded clinical and molecular data will be presented. [Table: see text]
The interdisciplinary team: Education as a means to exemplify and optimize patient outcomes in gastric/GEJ cancers through collaborative discussions.
Authors: Kinjal Parikh, Davecia Ragoonath Cameron, Pamela M. Peters
Journal: Journal of Clinical Oncology (2021)

248 Background: Care of patients with gastric/GEJ cancer involves multimodality treatment including various systemic and supportive approaches and collaboration of interdisciplinary team members. Optimizing care requires not only adherence to the latest evidence-based and guideline-driven recommendations but also the management of underlying comorbidities or treatment-induced conditions. This complex interplay of factors in treatment planning requires timely education for oncologists and nurses/NPs in both clinically driven topics and interdisciplinary collaboration. Methods: A series of 2 CME/CE-certified activities were launched to educate oncologists and nurses/NPs on the changing paradigms in gastric cancer as well as the interdisciplinary collaboration needed to optimize patient eligibility for treatment. Effectiveness was analyzed using 3 multiple-choice questions measuring knowledge and competence and 1 confidence question were presented as pre-/post- repeated pairs for each of the activities. Oncologists and nurses/NPs who completed both the pre- and post-CME questions were included in the analysis and McNemar’s tests were conducted to assess statistical significance of the results with p &lt; .05 being considered significant. The CME activities launched in 2/2020 with data collected and reported as of 9/2020. Results: 8034 learners participated in the activities including 1163 oncologists and 3665 nurses/NPs. Analyses from the activities found improvement in knowledge, competence, and confidence. Data from oncologists (n = 94-302) and nurses/NPs (n = 169-510) are reported. Statistically significant changes were seen for oncologists in: Knowledge regarding the impact of nutrition and anemia can have on quality-of-life (QOL) and further treatments (50% pre, 72% post; p &lt; .001); Competence related to implementing strategies to address nutrition and anemia to improve quality-of-life and to advance treatment (45% pre, 72% post; p &lt; .001); Confidence regarding their ability to work together as an integrated, interdisciplinary team to enhance quality of life and treatment outcomes through a holistic treatment approach (68% pre, 83% post; p &lt; .001). And for nurses/NPs in: Knowledge regarding the impact that nutrition and anemia can have on QOL and further treatments (34% pre, 50% post; p &lt; .01). Conclusions: This online, interactive, expert-led, CME/CE-certified educational activity resulted in gains in oncologist and nurse/NP knowledge, competence, and confidence surrounding advanced gastric/GEJ cancer management and team collaboration. As patients with gastric cancer continue to present with poor performance status and require not only systemic interventions but also amelioration of underlying conditions, education remains essential for optimal outcomes to members of the interdisciplinary team.
THU0453 THIRD OCCIPITAL NERVE RADIO-FREQUENCY UNDER FLUOROSCOPIC GUIDANCE IN MANAGEMENT OF CERVICOGENIC HEADACHE IN RHEUMATOID ARTHRITIS
Authors: A. Alawamy, M. Hassanien, E. Talaat, E. Kamel
Journal: Annals of the Rheumatic Diseases (2020)

Background: Rheumatoid arthritis is a common type of autoimmune arthritis characterized by chronic inflammation. Cervical spine is often affected specially in long lasting disease Objectives: Evaluate efficacy of Third occipital nerve Radiofrequency under fluoroscopic guidance to treat refractory cervicogenic headache in RA patients. Methods: The current study was revised and approved from the local ethical committee of Faculty of Medicine; Assiut University, then registered in the clinical trials under the number of NCT03852355 . Inclusion criteria included, Patients who fulfilled the American College of Rheumatology (ACR) (2010) criteria for RA and suffering from upper neck pain and/or headache due to bilateral 3rd occipital nerve involvement, excluding other local cervical spine pathologies was confirmed by MRI and previously failed conservative treatment for at least three months prior to enrollment. Sixty adult patients were randomly assigned to one of the two studied groups Group 1 (RF, n = 30), received bilateral Third occipital nerve Radiofrequency under fluoroscopic guidance or Group 2 (control group, n = 30), received oral prednisolone 10 mg/day. The two groups were then followed-up with neck disability index (NDI), nocturnal neck pain VAS score and headache score every two weeks for three months. Sleep disturbance, sleep disability index were reassessed six months post intervention. Post interventional assessment was done by pain physician who were kept blind to the grouping process. Results: Neck disability index (1ry outcome), Nocturnal pain VAS, and severity of headache showed significant differences during the whole post-interventional study period. The patients in RF group demonstrated significant improvement of pain in comparison to baseline value over the whole six months with p-value &lt; 0.001 as regard to the fore-mentioned three parameters. On the other aspect, the control group patients showed significant improvement in comparison to its baseline value after the 2nd, 12th and 24th weeks only as follows: (0.001,0.003, 0.003 for the NDI) (p values of 0.02,0.01, 0.01 for the nocturnal pain VAS), (0.001 0.009, 0.005 for the headache VAS severity. Conclusion: Radiofrequency of 3rd occipital nerve is effective in treatment of refractory cervicogenic headache in RA. Disclosure of Interests: : None declared
Preparing for a “dirty bomb” attack: the optimum mix of medical countermeasure resources
Authors: Alexis Rump, Patrick Ostheim, Stefan Eder, Cornelius Hermann, Michael Abend, Matthias Port
Journal: Military Medical Research (2021)

Abstract Background In radiological emergencies with radionuclide incorporation, decorporation treatment is particularly effective if started early. Treating all people potentially contaminated (“urgent treatment”) may require large antidote stockpiles. An efficacious way to reduce antidote requirements is by using radioactivity screening equipment. We analyzed the suitability of such equipment for triage purposes and determined the most efficient mix of screening units and antidote daily doses. Methods The committed effective doses corresponding to activities within the detection limits of monitoring portals and mobile whole-body counters were used to assess their usefulness as triage tools. To determine the optimal resource mix, we departed from a large-scale scenario (60,000 victims) and based on purchase prices of antidotes and screening equipment in Germany, we calculated efficiencies of different combinations of medical countermeasure resources by data envelopment analysis. Cost-effectiveness was expressed as the costs per life year saved and compared to risk reduction opportunities in other sectors of society as well as the values of a statistical life. Results Monitoring portals are adequate instruments for a sensitive triage after cesium-137 exposure with a high screening throughput. For the detection of americium-241 whole-body counters with a lower daily screening capacity per unit are needed. Assuming that 1% of the potentially contaminated patients actually need decorporation treatment, an efficient resource mix includes 6 monitoring portals and 25 mobile whole-body counters. The optimum mix depends on price discounts and in particular the fraction of victims actually needing treatment. The cost-effectiveness of preparedness for a “dirty bomb” attack is less than for common health care, but costs for a life year saved are less than for many risk-reduction interventions in the environmental sector. Conclusion To achieve economic efficiency a high daily screening capacity is of major importance to substantially decrease the required amount of antidote doses. Among the determinants of the number of equipment units needed, the fraction of the potentially contaminated victims that actually needs treatment is the most difficult to assess. Judging cost-effectiveness of the preparedness for “dirty bomb” attacks is an issue of principle that must be dealt with by political leaders.
Abstract 13531: Clinical Outcome and Major Adverse Events After Fontan Procedure -Fukuoka Fontan Study-
Authors: Yoshihiko Kodama, Kisho Ohtani, Ichiro Sakamoto, Kenichiro Yamamura, Tomomi Ide, Ayako Kuraoka, Yuichi Ishikawa, Makoto Nakamura, Kouichi Sagawa, Toshihide Nakano, Hideaki Kado, Shiro Ishikawa, Hiroyuki Tsutsui
Journal: Circulation (2017)

With the advancement of congenital heart disease management, most patients after Fontan procedure can now reach adulthood. However, the long-term outcome and risk factors for major adverse events a...
High Mobility Group Box 1 Protein (HMGB1) Mediates Anemia of Inflammation through Lineage Skewing and Direct Inhibition of EPO Signaling
Authors: Brian M Dulmovits, Julien Papoin, Jian Hua Li, Ryo Kurita, Yukio Nakamura, Yousef Al-Abed, Luanne L. Peters, Betty Diamond, Anupama Narla, Jeffrey M Lipton, Mohandas Narla, Kevin Tracey, Lionel Blanc
Journal: Blood (2017)
The Effect of Caloric Restriction and Aerobic Exercise on Serum FGF-23 in Patients with Moderate to Severe CKD
Authors: Elvis A. Akwo, Thomas G. Stewart, Cassianne Robinson-Cohen, Adriana Hung, Jonathan Himmelfarb, Katherine R. Tuttle, Talat Alp Ikizler
Journal: Journal of the American Society of Nephrology (2020)
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)
Authors: Amir Goldkorn, Catherine Tangen, Melissa Plets, Gareth J. Morrison, Alexander Cunha, Tong Xu, Jacek K. Pinski, Sue A. Ingles, Timothy Triche, Andrea L. Harzstark, Manish Kohli, Gary R. MacVicar, Daniel A. Vaena, Anthony W. Crispino, David J. McConkey, Primo N. Lara, Maha H.A. Hussain, David I. Quinn, Nicholas J. Vogelzang, Ian Murchie Thompson, Neeraj Agarwal
Journal: Clinical Cancer Research (2021)

In metastatic castrate-sensitive prostate cancer (mCSPC), combined androgen axis inhibition is a standard of care. Noninvasive biomarkers that guide initial therapy decisions are needed. We hypothesized that CellSearch circulating tumor cell (CTC) count, an FDA-cleared assay in metastatic castrate-resistant prostate cancer (mCRPC), is a relevant biomarker in mCSPC.SWOG S1216 is a phase III prospective randomized trial of androgen deprivation therapy (ADT) combined with orteronel or bicalutamide for mCSPC. CellSearch CTC count was measured at registration (baseline). Prespecified CTC cut-off points of 0, 1-4, and ≥5 were correlated with baseline patient characteristics and, in a stratified subsample, were also correlated with two prespecified trial secondary endpoints: 7-month PSA ≤0.2 ng/mL versus 0.2-4.0 versus >4.0 (intermediate endpoint for overall survival); and progression-free survival (PFS) ≤ versus >2 years.A total of 523 patients submitted baseline samples, and CTCs were detected (median 3) in 33%. Adjusting for two trial stratification factors (disease burden and timing of ADT initiation), men with undetectable CTCs had nearly nine times the odds of attaining 7-month PSA ≤ 0.2 versus > 4.0 [OR 8.8, 95% confidence interval (CI), 2.7-28.6, P < 0.001, N = 264] and four times the odds of achieving > 2 years PFS (OR 4.0, 95% CI, 1.9-8.5, P < 0.001, N = 336) compared with men with baseline CTCs ≥5.Baseline CTC count in mCSPC is highly prognostic of 7-month PSA and 2-year PFS after adjusting for disease burden and discriminates men who are likely to experience poor survival outcomes.
Abstract 14945: Efficacy and Safety of Intracoronary Thrombolysis as an Adjunctive Therapy to Primary Percutaneous Coronary Intervention in ST- Elevation Myocardial Infarction. A Systematic Review and Meta-Analysis
Authors: Motasem Alyamani, Sandra Campbell, Eliano Navarese, Robert C Welsh, Kevin R Bainey
Journal: Circulation (2019)

Background: Primary percutaneous coronary intervention (PPCI) is the preferred method of reperfusion in ST-elevation myocardial infarction (STEMI). However, during PPCI microvascular function may b...
Remdesivir in COVID-19 Patients with Impaired Renal Function
Authors: Sanna Gevers, Jan Welink, Cees van Nieuwkoop
Journal: Journal of the American Society of Nephrology (2021)

In their perspective, Adamsick et al.1 argue that, on the basis of its known pharmacokinetics, a 5-day course of remdesivir in patients with an eGFR of <30 ml/min per 1.73 m2 should be considered safe. Therefore, in their opinion, patients with coronavirus disease 2019 (COVID-19) who have impaired renal function should be offered remdesivir treatment, because this is a potentially life-saving treatment for such a vulnerable population. We agree with the authors that accumulation of the carrier sulfobutylether-β-cyclodextrin is likely to be of no concern because there is clinical experience with other agents, such as voriconazole. However, with respect to remdesivir and its metabolite GS-441524, to our knowledge, there are no human data to claim its safety in people with impaired renal function because they were excluded from the clinical trials.2 It should be emphasized that, in repeat-dose toxicity studies in rats and monkeys, the kidney (i.e., tubular epithelium) was identified as the primary target organ of remdesivir toxicity.3 Furthermore, although remdesivir exhibits low renal excretion as an intact drug (<10% of the administered dose), 49% was recovered as GS-441524, and a total of 74% of a radiolabeled dose was recovered in urine.3,4 Not surprisingly, a recent pharmacokinetic study showed higher GS-441524 levels in a patient with renal dysfunction.5 Apparently, because GS-441524 will be removed by hemodialysis, toxicity of remdesivir or its metabolite will not be an issue in patients who are already on hemodialysis.6 In contrast, in patients with COVID-19 and CKD, it cannot be excluded that remdesivir treatment might lead to an urgent need for RRT, and that remdesivir in this patient population might even have a negative risk-benefit ratio. The recent signal on potential renal side effects of remdesivir also holds concern about its use in patients with CKD.7 Therefore, we would like to discourage remdesivir as routine treatment in patients with COVID-19 and CKD (eGFR of <30 ml/min per 1.73 m3). Its use should be reserved to the context of clinical trials to improve our knowledge on safety and efficacy. Disclosures All authors have nothing to disclose. Funding None.
CD8<sup>+</sup> tumor-infiltrating lymphocyte infiltration prediction with radiomic signature in locally advanced rectal cancer.
Authors: Eui Kyu Chie, Seung Hyuck Jeon, Yu Jin Lim, Jaemoon Koh, Sehui Kim, Kyubo Kim
Journal: Journal of Clinical Oncology (2021)

123 Background: Despite increasing use of cancer immunotherapies, no biomarker relevant to anti-tumor immunity has been developed in rectal cancer. The present study aims to develop a radiomic signature to predict the infiltration of CD8 + tumor-infiltrating lymphocytes (TILs). Methods: In total, 131 patients undergoing neoadjuvant chemoradiotherapy (CRT) from 2005 to 2012 were analyzed. The study included pre-CRT dataset A ( n = 113; n = 75 and 38 for training and validation) and post-CRT datasets B ( n = 32; predominance of tumor) and C ( n = 20; pure fibrosis). To build the radiomic signature, 38 features selected from pre-CRT T2-weighted MRI scans were incorporated into the least absolute shrinkage and selection operator method. Results: Higher CD8 + TIL infiltration was associated with better overall and progression-free survival ( P = 0.01 and 0.03, respectively). In pre-CRT dataset A, the area under the receiver operating characteristic curve values of radiomic score for predicting CD8 + TILs were 0.760 and 0.729 for training and validation subsets, respectively. A significant correlation was observed between the radiomic signature and CD8 + TIL density in the post-CRT dataset B (Pearson’s R = ‒0.372, P = 0.036), whereas no association was found within the dataset C accounting for pure fibrosis after CRT (Pearson’s R = ‒0.069, P = 0.77). Conclusions: We established the MRI-derived radiomic signature for predicting CD8 + TIL infiltration in the contemporary treatment era of rectal cancer. The noninvasive characterization of tumor immune status would provide insights into the role of radiomic-pathology modeling to predict the local immune phenotypes.
RhoG deficiency abrogates cytotoxicity of human lymphocytes and causes hemophagocytic lymphohistiocytosis
Authors: Artem Kalinichenko, Giovanna Perinetti Casoni, Loïc Dupré, Luca Trotta, Jakob Huemer, Donatella Galgano, Yolla German, Ben Haladik, Julia Pazmandi, Marini Thian, Özlem Yüce Petronczki, Samuel C. Chiang, Mervi Taskinen, Anne Hekkala, Saila Kauppila, Outi Lindgren, Terhi Tapiainen, Michael J. Kraakman, Kim Vettenranta, Alexis J. Lomakin, Janna Saarela, Mikko R. J. Seppänen, Yenan T. Bryceson, Kaan Boztug
Journal: Blood (2021)
Clinical Use of CMV-Specific T Cells Derived from CMV-Naïve Donors
Authors: Patrick Hanley, Michael Keller, Lauren Roesch, Devin Saunders, Haili Lang, Blachy Davila, Ulrich A. Duffner, Divyesh Kukadiya, Fahmida Hoq, Catherine M. Bollard
Journal: Blood (2017)